SSX2 and plasma cell myeloma: In the ten myeloma patients analyzed, T-cell responses against MAGE-C1 and hTERT were detected in 80% of subjects; against NY-ESO-1 in 70%, MAGE-A3 in 50%, PRAME and SSX2 in 30%, p53 in 2, and WT-1 in only 10%.